Table 3.
Relative standardized Incidence Ratios (RSIRs)1 and 95% confidence intervals (CI) adjusted for age, year, race, and sex
| Private Applicators | Commercial Applicators | Spouses | |||||||
|---|---|---|---|---|---|---|---|---|---|
| N | RSIR | CI | N | RSIR | CI | N | RSIR | CI | |
| Oral Cavity and Pharynx | 198 | 0.76 | (0.66, 0.88) | 10 | 0.59 | (0.31, 1.10) | 44 | 0.80 | (0.59, 1.08) |
| Lip | 63 | 2.46 | (1.92, 3.16) | 4 | – | – | 7 | 1.98 | (0.94, 4.16) |
| Tongue | 35 | 0.50 | (0.36, 0.70) | 2 | – | – | 15 | 1.00 | (0.60, 1.66) |
| Tonsil | 27 | 0.52 | (0.35, 0.75) | 1 | – | – | 3 | – | – |
| Digestive System | 140 7 | 0.95 | (0.90, 1.01) | 84 | 1.00 | (0.79, 1.27) | 540 | 0.90 | (0.82, 0.98) |
| Esophagus | 102 | 0.78 | (0.64, 0.95) | 13 | 1.57 | (0.90, 2.73) | 9 | 0.57 | (0.30, 1.10) |
| Stomach | 114 | 1.01 | (0.84, 1.21) | 2 | – | – | 28 | 0.87 | (0.60, 1.26) |
| Small Intestine | 44 | 1.25 | (0.93, 1.69) | 4 | – | – | 11 | 0.68 | (0.38, 1.23) |
| Colon and Rectum | 842 | 1.06 | (0.98, 1.13) | 49 | 1.08 | (0.80, 1.45) | 346 | 0.97 | (0.87, 1.08) |
| Proximal Colon | 310 | 1.04 | (0.93, 1.17) | 17 | 1.07 | (0.66, 1.73) | 169 | 1.05 | (0.90, 1.22) |
| Distal Colon | 226 | 1.10 | (0.96, 1.25) | 13 | 1.11 | (0.64, 1.93) | 84 | 1.02 | (0.82, 1.27) |
| Rectum and Rectosigmoid Junction | 260 | 1.05 | (0.93, 1.19) | 17 | 1.07 | (0.66, 1.73) | 74 | 0.84 | (0.67, 1.06) |
| Anus, Anal Canal and Anorectum | 8 | 0.49 | (0.24, 0.97) | 1 | – | – | 6 | 0.34 | (0.15, 0.76) |
| Liver and Intrahepatic Bile Duct | 78 | 0.62 | (0.50, 0.77) | 4 | – | – | 21 | 0.79 | (0.52, 1.22) |
| Pancreas | 183 | 0.92 | (0.79, 1.06) | 10 | 0.92 | (0.49, 1.71) | 71 | 0.77 | (0.61, 0.97) |
| Peritoneum, Omentum and Mesentery | 1 | – | – | 0 | – | – | 21 | 2.02 | (1.32, 3.10) |
| Respiratory System | 881 | 0.51 | (0.47, 0.54) | 56 | 0.75 | (0.57, 0.99) | 259 | 0.41 | (0.36, 0.47) |
| Larynx | 66 | 0.53 | (0.42, 0.68) | 4 | – | – | 5 | 0.30 | (0.12, 0.71) |
| Lung and Bronchus | 807 | 0.52 | (0.48, 0.55) | 51 | 0.78 | (0.58, 1.04) | 252 | 0.42 | (0.37, 0.48) |
| Small-Cell Carcinoma | 138 | 0.63 | (0.53, 0.75) | 10 | 0.97 | (0.52, 1.82) | 39 | 0.37 | (0.27, 0.51) |
| Non-Small Cell Carcinoma | 633 | 0.53 | (0.49, 0.58) | 40 | 0.78 | (0.56, 1.08) | 199 | 0.46 | (0.40, 0.53) |
| Squamous Cell Carcinoma | 209 | 0.55 | (0.48, 0.64) | 15 | 0.97 | (0.58, 1.62) | 42 | 0.44 | (0.32, 0.59) |
| Adenocarcinoma | 238 | 0.58 | (0.51, 0.66) | 16 | 0.74 | (0.45, 1.21) | 106 | 0.56 | (0.46, 0.67) |
| Large-Cell Carcinoma | 68 | 0.43 | (0.34, 0.54) | 3 | – | – | 9 | 0.18 | (0.10, 0.35) |
| Melanoma of the Skin | 393 | 1.12 | (1.01, 1.24) | 26 | 1.25 | (0.84, 1.86) | 177 | 1.37 | (1.18, 1.60) |
| Breast | 63 | 0.95 | (0.74, 1.22) | 2 | – | – | 138 9 | 1.28 | (1.20, 1.37) |
| Female Genital System | 21 | 1.05 | (0.68, 1.61) | 2 | – | – | 498 | 1.10 | (1.00, 1.21) |
| Cervix Uteri | 3 | – | – | 0 | – | – | 29 | 0.56 | (0.39, 0.81) |
| Corpus and Uterus | 6 | 0.54 | (0.24, 1.21) | 1 | – | – | 323 | 1.30 | (1.16, 1.46) |
| Ovary and Fallopian Tube | 11 | 1.99 | (1.10, 3.59) | 0 | – | – | 122 | 0.97 | (0.81, 1.16) |
| Male Genital System | 322 8 | 1.44 | (1.38, 1.51) | 157 | 1.36 | (1.12, 1.65) | 11 | 1.00 | (0.55, 1.80) |
| Prostate | 316 9 | 1.44 | (1.38, 1.50) | 149 | 1.33 | (1.09, 1.62) | 11 | 1.01 | (0.56, 1.83) |
| Testis | 45 | 1.45 | (1.08, 1.94) | 7 | 1.55 | (0.73, 3.27) | 0 | – | – |
| Urinary System | 740 | 0.87 | (0.80, 0.93) | 39 | 0.84 | (0.61, 1.17) | 154 | 0.84 | (0.72, 0.99) |
| Urinary Bladder | 411 | 0.76 | (0.69, 0.84) | 26 | 1.00 | (0.67, 1.49) | 60 | 0.71 | (0.55, 0.92) |
| Kidney and Renal Pelvis | 314 | 1.06 | (0.95, 1.19) | 12 | 0.63 | (0.36, 1.12) | 92 | 0.98 | (0.80, 1.21) |
| Brain | 87 | 0.87 | (0.70, 1.07) | 6 | 0.86 | (0.39, 1.93) | 49 | 1.12 | (0.85, 1.49) |
| Endocrine System | 92 | 1.30 | (1.06, 1.60) | 12 | 1.92 | (1.08, 3.41) | 123 | 1.36 | (1.14, 1.63) |
| Thyroid | 82 | 1.28 | (1.03, 1.59) | 11 | 1.88 | (1.03, 3.42) | 118 | 1.36 | (1.13, 1.63) |
| Papillary Carcinoma | 66 | 1.32 | (1.03, 1.68) | 8 | 1.65 | (0.82, 3.33) | 110 | 1.48 | (1.22, 1.79) |
| All Lymphohematopoietic | 830 | 1.20 | (1.11, 1.29) | 40 | 0.90 | (0.65, 1.25) | 330 | 1.13 | (1.01, 1.27) |
| Lymphoid Malignancies | 700 | 1.21 | (1.12, 1.31) | 36 | 0.98 | (0.70, 1.38) | 290 | 1.18 | (1.04, 1.33) |
| Hodgkin Lymphoma | 27 | 1.09 | (0.75, 1.60) | 2 | – | – | 10 | 0.98 | (0.53, 1.82) |
| B-Cell Lymphoma | 624 | 1.26 | (1.16, 1.36) | 32 | 1.02 | (0.71, 1.46) | 265 | 1.24 | (1.09, 1.41) |
| Chronic Lymphocytic Leukemia | 166 | 1.30 | (1.11, 1.51) | 9 | 1.11 | (0.58, 2.16) | 43 | 0.98 | (0.73, 1.33) |
| Diffuse Large B-Cell Lymphoma | 145 | 1.29 | (1.10, 1.52) | 5 | 0.67 | (0.28, 1.63) | 70 | 1.39 | (1.09, 1.76) |
| Marginal Zone Lymphoma | 16 | 0.67 | (0.41, 1.10) | 2 | – | – | 25 | 1.64 | (1.11, 2.44) |
| Follicular Lymphoma | 81 | 1.27 | (1.02, 1.58) | 7 | 1.51 | (0.72, 3.18) | 54 | 1.50 | (1.15, 1.96) |
| Multiple Myeloma | 146 | 1.30 | (1.11, 1.54) | 5 | 0.86 | (0.35, 2.06) | 57 | 1.17 | (0.90, 1.52) |
| T-Cell Lymphoma | 27 | 0.98 | (0.67, 1.43) | 1 | – | – | 8 | 0.77 | (0.39, 1.55) |
| Leukemia | 145 | 1.22 | (1.04, 1.44) | 7 | 0.99 | (0.47, 2.08) | 45 | 0.99 | (0.74, 1.33) |
| Lymphocytic Leukemia | 14 | 0.85 | (0.50, 1.44) | 2 | – | – | 5 | 0.90 | (0.38, 2.17) |
| Myeloid and Monocytic Leukemia | 115 | 1.24 | (1.03, 1.49) | 4 | – | – | 38 | 1.05 | (0.76, 1.45) |
| Acute Myeloid/Monocytic Leukemia | 86 | 1.42 | (1.15, 1.76) | 3 | – | – | 33 | 1.36 | (0.96, 1.91) |
| Chronic Myeloid Leukemia | 25 | 0.84 | (0.57, 1.25) | 1 | – | – | 5 | 0.46 | (0.19, 1.10) |
| Mesothelioma | 21 | 0.94 | (0.61, 1.44) | 0 | – | – | 4 | – | – |
| Myelodysplastic/Myeloproliferativ e Neoplasm2 | 87 | 0.89 | (0.72, 1.10) | 0 | – | – | 38 | 0.87 | (0.63, 1.20) |
| Myelodysplastic Syndrome | 48 | 0.93 | (0.70, 1.24) | 0 | – | – | 19 | 1.06 | (0.68, 1.67) |
| Myeloproliferative Neoplasm | 36 | 0.83 | (0.60, 1.15) | 0 | – | – | 16 | 0.66 | (0.40, 1.07) |
1
Ratio of the SIR for the cancer site of interest to the SIR for all cancers except the cause of interest
2
Analyses restricted to 2001-on when these tumors became reportable to central cancer registries